Terri Telle, MD
Family Medicine · Paducah, KYNPI 1699772244
Payments from drug & device makers
Across 476 payments — averaging $13.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Novo Nordisk$925
- Lilly USA, LLC$783
- Pfizer$579
- Amgen$367
- Astellas Pharma US Inc$269
- plus $2K from 32 others
What the payments were for
- Food & beverage$6,15398%
- Education$1202%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 91 | $1,026 |
| Novo Nordisk | 92 | $925 |
| Lilly USA, LLC | 63 | $783 |
| Pfizer | 44 | $579 |
| Amgen | 26 | $367 |
| Astellas Pharma US Inc | 12 | $269 |
| Supernus Pharmaceuticals, Inc. | 12 | $238 |
| Corium, LLC | 16 | $216 |
| Boehringer Ingelheim | 11 | $183 |
| Sanofi-aventis U.S. LLC | 14 | $183 |
| AstraZeneca | 11 | $149 |
| Ironshore Pharmaceuticals Inc. | 5 | $136 |
| Amarin Pharma, Inc. | 9 | $125 |
| Johnson & Johnson | 7 | $113 |
| Merck | 8 | $95 |
| Novartis | 4 | $83 |
| Dexcom, Inc. | 4 | $80 |
| Bayer | 5 | $74 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $65 |
| Medtronic | 2 | $65 |
| GSK | 4 | $60 |
| Biohaven Pharmaceuticals, Inc. | 4 | $54 |
| Exact Sciences | 3 | $51 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $47 |
| Sumitomo Pharma America, Inc. | 3 | $44 |
| Sunovion Pharmaceuticals Inc. | 3 | $44 |
| Idorsia Pharmaceuticals US Inc | 3 | $39 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $28 |
| Xeris Pharmaceuticals, Inc. | 1 | $20 |
| Abbott | 1 | $17 |
| Ironwood Pharmaceuticals, Inc | 1 | $17 |
| Tandem Diabetes Care, Inc. | 1 | $16 |
| Mylan Specialty L.p. | 1 | $16 |
| Hologic Sales And Service, LLC | 1 | $15 |
| Shire North American Group Inc | 1 | $14 |
| Sanofi Pasteur Inc. | 1 | $12 |
| AMAG Pharmaceuticals, Inc. | 1 | $12 |
| Kowa Pharmaceuticals America, Inc. | 1 | $11 |
How this compares
$6,273 in reported general payments places this provider in the 85th percentile of 1,559 family medicine providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 143 | $224,228 |
| EliquisApixaban | 120 | $107,384 |
| TrulicityDulaglutide | 59 | $101,053 |
| JardianceEmpagliflozin | 59 | $73,374 |
| RybelsusSemaglutide | 27 | $50,273 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 28 | $36,956 |
| FarxigaDapagliflozin Propanediol | 30 | $29,130 |
| MounjaroTirzepatide | 16 | $27,213 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 15 | $24,371 |
| MyrbetriqMirabegron | 43 | $23,985 |
| RytaryCarbidopa/Levodopa | 21 | $18,313 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 94 | $17,787 |
| XareltoRivaroxaban | 16 | $16,240 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 17 | $14,227 |
| JanumetSitagliptin Phos/Metformin Hcl | 14 | $12,386 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $925 | $274,501170 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $783 | $128,26675 claims |
| PfizerEliquis | $579 | $107,384120 claims |
| Boehringer IngelheimJardiance | $183 | $73,37459 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $149 | $43,35747 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $183 | $36,95628 claims |
| GSKTrelegy Ellipta, Incruse Ellipta | $60 | $28,62027 claims |
| Astellas Pharma US IncMyrbetriq | $269 | $23,98543 claims |
| AbbVieLinzess, Synthroid | $1,026 | $18,002122 claims |
| MerckJanumet, Dulera | $95 | $16,68525 claims |
| Johnson & JohnsonXarelto | $113 | $16,24016 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $44 | $12,12217 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,559 family medicine providers in Kentucky.
Other family medicine in Paducah
- James TurnboPaducah$124K
- Joseph WigginsPaducah$55K
- Jeffrey RineyPaducah$49K
- James EickholzPaducah$14K
- Brian SmithVersailles$7.7M
- Barbara Fleming-PhillipsLexington$1.4M
- Christopher RhyneLouisville$1M
- Kruti PatelBurlington$463K
- Michael LovelaceLouisville$244K
- John RichardLexington$226K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.